Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Multiple Myeloma 3 Lymphoma 3 Lung Neoplasms 3 Endometrial Neoplasms 3 Urinary Bladder Neoplasms 2 Ovarian Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Renal Cell 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Somatostatinoma 1 Sarcoma 1 Recurrent Lung Squamous Cell Carcinoma 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Metastatic Castration-Resistant Prostate Cancer 1 Melanoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1 Glioma 1 Genital Diseases 1 Fallopian Tube Neoplasms 1

Interventions

Doxorubicin 62 Ifosfamide 39 Gemcitabine 29 Radiotherapy 27 Filgrastim 27 Cyclophosphamide 26 Docetaxel 19 Vincristine 18 pembrolizumab 17 Etoposide 17 pazopanib 16 Cisplatin 16 Nivolumab 15 Trabectedin 14 apatinib 13 Magnetic Resonance Spectroscopy 13 Carboplatin 12 Irinotecan 11 Bevacizumab 11 anlotinib 10 Temozolomide 10 Surgical Procedures, Operative 10 Sirolimus 10 camrelizumab 9 Sorafenib 9 Paclitaxel 9 Ipilimumab 9 Injections 9 Dactinomycin 9 Topotecan 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Sarcoma × sapanisertib × Clear all

NCT02987959 2022-10-14

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

Fox Chase Cancer Center

Phase 2 Terminated

6 enrolled 10 charts

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡